Asparagine synthethase: A new potential biomarker in ovarian cancer

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the NCI-60 cell line panel has served as a biomarker discovery platform and has led to the identification of a correlation between L-ASP efficacy and asparagine synthetase (ASNS) expression in cultured cells. The presence of that correlation in the ovarian subpanel of the NCI-60 has made a case for repositioning L-ASP to ovarian cancer. This review presents an overview of the biomarker development process, summarizes the efforts that have been invested thus far in developing ASNS as a biomarker for ovarian cancer treatment, highlights the role of RNAi and the limitations of the NCI-60 in that process, and addresses important considerations for next steps in the development of ASNS as a predictive biomarker.

Original languageEnglish (US)
Pages (from-to)61-64
Number of pages4
JournalDrug News and Perspectives
Volume22
Issue number1
DOIs
StatePublished - Jan 2009

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Asparagine synthethase: A new potential biomarker in ovarian cancer'. Together they form a unique fingerprint.

Cite this